Fondation ARC   Report issue

Foundation Phase 2 Phase 3
Founded: Villejuif France (1962)

Organization Overview

First Clinical Trial
1999
NCT00169130
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ARC Foundation for Cancer Research | Fondation ARC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anus Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Disease Progression (Phase 2)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Penile Neoplasms (Phase 2)

Preleukemia (Phase 2)

Rectal Neoplasms (Phase 2)

Sarcoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Vulvar Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 46